On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €115.00. The ...

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

BCC Research reveals in its new report, OTC Drugs, Medical Devices, and Diagnostics: Global Markets, the over-the-counter ...

Both GenZ and Millennials are growing more self-assured about maneuvering romantic connections, even though the two ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

Quarterly business operating income, excluding one-off items, rose 20.1% to 2.90 billion euros ($3.29 billion), surpassing the average analyst estimate of 2.68 billion euros. The company reported net ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...